Search
Cerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[L51339] It was also approved by the EMA on May 30, 2017 [L51324] and by Health Canada on December 19, 2018. … [L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency.
Categories: Hydrolytic Lysosomal N-terminal Tripeptidyl PeptidaseSulbactam
go.drugbank.com/drugs/DB09324ApprovedInvestigational[L50131] When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.[A263296]
Octreotide
go.drugbank.com/drugs/DB00104ApprovedInvestigationalThis drug was developed by Chiasma Inc.[L14495,L14507,L14528] … [L14513] In the past, octreotide has been administered solely by injection.
Mirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigationalMirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide … This decision was supported by findings from the phase 3 SORAYA trial (NCT04296890).[L43967,L43972] It was subsequently granted full approval in March 2024.
Halazepam
go.drugbank.com/drugs/DB00801ApprovedIllicitWithdrawn[A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229] … [A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam.
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis. … Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub
Lactulose
go.drugbank.com/drugs/DB00581ApprovedInvestigational[L6202] Nevertheless, although lactulose received formal FDA approval in 1977 and has since become a readily available generic and brand-name non-prescription medication listed on the World Health … and its first clinical use for treating PSE was not until 1966.
Synonyms: 4-O-beta-D-Galactopyranosyl-D-fructose, 4-O-beta-D-Galactopyranosyl-D-fructofuranoseBaloxavir marboxil
go.drugbank.com/drugs/DB13997ApprovedInvestigational[L4779] It was also approved by the European Commission on January 7, 2021.[L45241] … [A251760] Baloxavir marboxil was first globally approved in Japan in February 2018,[A39895] followed by the US approval in October, 2018.
Brensocatib
go.drugbank.com/drugs/DB15638ApprovedNon-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by airway widening, mucus accumulation, and neutrophilic inflammation. … [A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813]
Synonyms: (S)-N-((S)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamideFollitropin
go.drugbank.com/drugs/DB00066ApprovedInvestigationalFurther, the ogliosaccharide side chains are very similar, but not completely identical to that of natural FSH. However, these small differences do not affect the bioactivity compared to natural FSH. … However, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but